These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19683238)

  • 1. Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a.
    Speidl WS; Katsaros KM; Kastl SP; Zorn G; Huber K; Maurer G; Wojta J; Christ G
    Atherosclerosis; 2010 Jan; 208(1):285-9. PubMed ID: 19683238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis.
    Habara S; Iwabuchi M; Inoue N; Nakamura S; Asano R; Nanto S; Hayashi Y; Shiode N; Saito S; Ikari Y; Kimura T; Hosokawa J; Nakamura M; Kotani J; Kozuma K; Mitsudo K
    Am Heart J; 2013 Sep; 166(3):527-33. PubMed ID: 24016503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of percutaneous treatment of in-stent restenosis with drug-eluting stents: results from the first phase of the prospective multicentre German DES.DE registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Sabin G; Tebbe U; Hochadel M; Senges J; Akin I; Kuck KH; Hamm C; Richardt G;
    EuroIntervention; 2011 Jun; 7(2):201-8. PubMed ID: 21646062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).
    Alfonso F; Pérez-Vizcayno MJ; Dutary J; Zueco J; Cequier A; García-Touchard A; Martí V; Lozano I; Angel J; Hernández JM; López-Mínguez JR; Melgares R; Moreno R; Seidelberger B; Fernández C; Hernandez R;
    JACC Cardiovasc Interv; 2012 Jul; 5(7):728-37. PubMed ID: 22814777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
    Ramsdale DR; Rao A; Asghar O; Ramsdale KA; McKay E
    J Invasive Cardiol; 2008 Oct; 20(10):493-500. PubMed ID: 18829991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
    Spadaccio C; Patti G; De Marco F; Coccia R; Di Domenico F; Pollari F; Zanzonico R; Pettinari M; Lusini M; Di Sciascio G; Covino E; Chello M
    Am J Cardiol; 2013 Jul; 112(1):21-6. PubMed ID: 23561587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
    Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
    J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis.
    Maluenda G; Ben-Dor I; Gaglia MA; Wakabayashi K; Mahmoudi M; Sardi G; Laynez-Carnicero A; Torguson R; Xue Z; Margulies AD; Suddath WO; Kent KM; Bernardo NL; Satler LF; Pichard AD; Waksman R
    Circ Cardiovasc Interv; 2012 Feb; 5(1):12-9. PubMed ID: 22319069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
    Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
    J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.
    Katsaros KM; Speidl WS; Kastl SP; Zorn G; Huber K; Maurer G; Glogar D; Wojta J; Christ G
    J Thromb Haemost; 2008 Mar; 6(3):508-13. PubMed ID: 18182031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary treatment of in-stent restenosis and the incidence of recurrent in-stent restenosis in the era of drug-eluting stents.
    Ajani AE; Yan BP; Clark DJ; Eccleston D; Walton A; Lew R; Meehan A; Brennan A; Reid C; Duffy SJ;
    Heart Lung Circ; 2007 Aug; 16(4):269-73. PubMed ID: 17419097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activation of complement and serial changes of anaphylatoxin (C3a, C5a) in patients for open-heart surgery using a membrane oxygenator].
    Mitsuhata H; Enzan K; Hasegawa J; Matumoto S; Matsumoto J; Kurosawa S
    Masui; 1992 Feb; 41(2):194-9. PubMed ID: 1552659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of serum visfatin in predicting in-stent restenosis of drug-eluting stents.
    Wu XA; Xie G; Li XQ; Wu HT; Wang X
    Clin Chim Acta; 2018 Apr; 479():20-24. PubMed ID: 29305846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
    Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.